MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319944 | Name: Ulipristal acetate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ulipristal acetate, also known as CDB-2914, is a selective progesterone receptor modulator (SPRM) approved for contraception, and for uterine fibroid. As a SPRM, ulipristal acetate has partial agonistic as well as antagonistic effects on the progesterone receptor. It also binds to the glucocorticoid receptor, but is only a weak antiglucocorticoid relative to mifepristone, and has no relevant affinity to the estrogen, androgen and mineralocorticoid receptors.

Chemical Structure

Ulipristal acetate
Ulipristal acetate
CAS#126784-99-4 (acetate)

Theoretical Analysis

MedKoo Cat#: 319944

Name: Ulipristal acetate

CAS#: 126784-99-4 (acetate)

Chemical Formula: C30H37NO4

Exact Mass: 0.0000

Molecular Weight: 475.63

Elemental Analysis: C, 75.76; H, 7.84; N, 2.94; O, 13.46

Price and Availability

Size Price Availability Quantity
50mg USD 150.00 Ready to ship
100mg USD 220.00 Ready to ship
200mg USD 350.00 Ready to ship
500mg USD 550.00 Ready to ship
1g USD 950.00 Ready to ship
2g USD 1,650.00 Ready to ship
5g USD 3,650.00 Ready to ship
10g USD 6,150.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
159811-51-5 126784-99-4 (acetate)
Synonym
CDB-2914, CDB 2914, CDB2914, HRP-2000, HRP 2000, HRP2000, VA2914, VA-2914, VA 2914, RTI 3021-012, RU 44675, Ulipristal acetate, EllaOne, Ella, Esmya
IUPAC/Chemical Name
(8S,11R,13S,14S,17R)-17-acetyl-11-(4-(dimethylamino)phenyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate
InChi Key
OOLLAFOLCSJHRE-ZHAKMVSLSA-N
InChi Code
InChI=1S/C30H37NO4/c1-18(32)30(35-19(2)33)15-14-27-25-12-8-21-16-23(34)11-13-24(21)28(25)26(17-29(27,30)3)20-6-9-22(10-7-20)31(4)5/h6-7,9-10,16,25-27H,8,11-15,17H2,1-5H3/t25-,26+,27-,29-,30-/m0/s1
SMILES Code
CC([C@@]1(OC(C)=O)CC[C@@]2([H])[C@]3([H])CCC4=CC(CCC4=C3[C@@H](C5=CC=C(N(C)C)C=C5)C[C@]12C)=O)=O
Appearance
White to off-white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Ulipristal acetate (CDB-2914, HRP 2000, RU 44675) is a selective SPRM for emergency contraception.
In vitro activity:
As shown in Figure 2A and 2B, normal myometrial cells were not significantly affected by 5 μM UPA (Ulipristal). On the contrary, in UPA-treated leiomyoma cells both the LC3-II level and the LC3-II:LC3-I ratio were significantly increased compared with untreated, control cells. The autophagic process occurring in leiomyoma cells was also confirmed by cotreating cells with CQ, which inhibits the fusion of autophagosomes with lysosomes, thus inhibiting the clearance of LC3-II. The resulting further accumulation of LC3-II indicates that an autophagic flux is actually taking place. As shown in Figure 2C, the cotreatment with CQ increased LC3-II protein level in leiomyoma cells, particularly in UPA-treated ones, suggesting that UPA actually stimulated the autophagic flux. Reference: Fertil Steril. 2019 Dec;112(6):1150-1159. https://pubmed.ncbi.nlm.nih.gov/31843092/
In vivo activity:
To define the physiological significance of ulipristal on glucocorticoid signaling in vivo, this study exposed female C57Bl/6 mice to 2 mg/kg ulipristal for 4 hours. Acute exposure to ulipristal resulted in tissue-specific effects on basal glucocorticoid signaling, including antagonist, agonist, and no effects. In the lung, ulipristal significantly reduced transcript levels of Per1 and Fkbp5 but not Gilz (Fig. 8A). Consistent with the findings in Hepg2 and UtLM cells, transcript levels of Per1, Fkbp5, and Gilz were significantly decreased by ulipristal in the liver and the uterus (Fig. 8A). However, no effect of ulipristal exposure was evident on the basal expression of the glucocorticoid-responsive genes Per1, Fkbp5, and Gilz in the spleen (Fig. 8B). Interestingly, exposure to ulipristal induced the expression of Fkbp5 and Gilz mRNA in the hippocampus and pituitary (Fig. 8C), suggesting that ulipristal may act as an agonist of glucocorticoid signaling in certain tissues. Reference: J Clin Endocrinol Metab. 2020 Mar; 105(3): 716–734. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112983/
Solvent mg/mL mM
Solubility
DMSO 56.5 118.79
DMF 30.0 63.07
Ethanol 22.0 46.25
Ethanol:PBS (pH 7.2) (1:1) 0.2 0.42
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 475.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Del Bello B, Marcolongo P, Ciarmela P, Sorbi F, Petraglia F, Luisi S, Maellaro E. Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study. Fertil Steril. 2019 Dec;112(6):1150-1159. doi: 10.1016/j.fertnstert.2019.08.007. PMID: 31843092. 2. Shin SJ, Kim J, Lee S, Baek J, Lee JE, Cho C, Ha E. Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix. Int J Mol Med. 2018 Oct;42(4):1857-1864. doi: 10.3892/ijmm.2018.3779. Epub 2018 Jul 17. PMID: 30015921; PMCID: PMC6108884. 3. Small B, Millard CEF, Kisanga EP, Burman A, Anam A, Flannery C, Al-Hendy A, Whirledge S. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor. J Clin Endocrinol Metab. 2020 Mar 1;105(3):716–34. doi: 10.1210/clinem/dgz139. PMID: 31665442; PMCID: PMC7112983. 4. Gómez-Elías MD, Munuce MJ, Bahamondes L, Cuasnicú PS, Cohen DJ. In vitro and in vivo effects of ulipristal acetate on fertilization and early embryo development in mice. Hum Reprod. 2016 Jan;31(1):53-9. doi: 10.1093/humrep/dev287. Epub 2015 Nov 17. PMID: 26582845.
In vitro protocol:
1. Del Bello B, Marcolongo P, Ciarmela P, Sorbi F, Petraglia F, Luisi S, Maellaro E. Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study. Fertil Steril. 2019 Dec;112(6):1150-1159. doi: 10.1016/j.fertnstert.2019.08.007. PMID: 31843092. 2. Shin SJ, Kim J, Lee S, Baek J, Lee JE, Cho C, Ha E. Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix. Int J Mol Med. 2018 Oct;42(4):1857-1864. doi: 10.3892/ijmm.2018.3779. Epub 2018 Jul 17. PMID: 30015921; PMCID: PMC6108884.
In vivo protocol:
1. Small B, Millard CEF, Kisanga EP, Burman A, Anam A, Flannery C, Al-Hendy A, Whirledge S. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor. J Clin Endocrinol Metab. 2020 Mar 1;105(3):716–34. doi: 10.1210/clinem/dgz139. PMID: 31665442; PMCID: PMC7112983. 2. Gómez-Elías MD, Munuce MJ, Bahamondes L, Cuasnicú PS, Cohen DJ. In vitro and in vivo effects of ulipristal acetate on fertilization and early embryo development in mice. Hum Reprod. 2016 Jan;31(1):53-9. doi: 10.1093/humrep/dev287. Epub 2015 Nov 17. PMID: 26582845.
1: Sancho JM, Delgado VS, Valero MJ, Soteras MG, Amate VP, Carrascosa AA. Hysteroscopic myomectomy outcomes after 3-month treatment with either Ulipristal Acetate or GnRH analogues: a retrospective comparative study. Eur J Obstet Gynecol Reprod Biol. 2016 Mar;198:127-30. doi: 10.1016/j.ejogrb.2016.01.014. Epub 2016 Jan 21. Review. PubMed PMID: 26871272. 2: Rosato E, Farris M, Bastianelli C. Mechanism of Action of Ulipristal Acetate for Emergency Contraception: A Systematic Review. Front Pharmacol. 2016 Jan 12;6:315. doi: 10.3389/fphar.2015.00315. eCollection 2015. Review. PubMed PMID: 26793107; PubMed Central PMCID: PMC4709420. 3: Puchar A, Luton D, Koskas M. Ulipristal acetate for uterine fibroid-related symptoms. Drugs Today (Barc). 2015 Nov;51(11):661-7. doi: 10.1358/dot.2015.51.11.2413469. Review. PubMed PMID: 26744741. 4: Jatlaoui TC, Riley H, Curtis KM. Safety data for levonorgestrel, ulipristal acetate and Yuzpe regimens for emergency contraception. Contraception. 2016 Feb;93(2):93-112. doi: 10.1016/j.contraception.2015.11.001. Epub 2015 Nov 3. Review. PubMed PMID: 26546020. 5: Trefoux Bourdet A, Luton D, Koskas M. Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence. Int J Womens Health. 2015 Mar 26;7:321-30. doi: 10.2147/IJWH.S50016. eCollection 2015. Review. PubMed PMID: 25848323; PubMed Central PMCID: PMC4381886. 6: Tafi E, Scala C, Leone Roberti Maggiore U, Bizzarri N, Candiani M, Venturini PL, Ferrero S. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. Expert Opin Drug Saf. 2015 Jun;14(6):965-77. doi: 10.1517/14740338.2015.1021773. Epub 2015 Mar 14. Review. PubMed PMID: 25772793. 7: Galliano D. Ulipristal acetate in uterine fibroids. Fertil Steril. 2015 Feb;103(2):359-60. doi: 10.1016/j.fertnstert.2014.11.028. Epub 2014 Dec 30. Review. PubMed PMID: 25555419. 8: Pérez-López FR. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues. Climacteric. 2015 Apr;18(2):177-81. doi: 10.3109/13697137.2014.981133. Epub 2014 Nov 12. Review. PubMed PMID: 25390187. 9: Pohl O, Zobrist RH, Gotteland JP. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015 Apr;22(4):476-83. doi: 10.1177/1933719114549850. Epub 2014 Sep 16. Review. PubMed PMID: 25228633; PubMed Central PMCID: PMC4812693. 10: Glasier A. The rationale for use of Ulipristal Acetate as first line in emergency contraception: biological and clinical evidence. Gynecol Endocrinol. 2014 Oct;30(10):688-90. doi: 10.3109/09513590.2014.950645. Epub 2014 Aug 18. Review. PubMed PMID: 25133564. 11: Goldstajn MS, Baldani DP, Skrgatić L, Radaković B, Vrbić H, Canić T. Ulipristal acetate in emergency contraception. Coll Antropol. 2014 Mar;38(1):379-84. Review. PubMed PMID: 24851646. 12: Ulipristal Acetate (Fibristal) (5 mg Tablets): Treatment of Moderate to Severe Signs and Symptoms of Uterine Fibroids in Adult Women of Reproductive Age Who are Eligible for Surgery. The Duration of Treatment is Limited to Three Months [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Dec. Available from http://www.ncbi.nlm.nih.gov/books/NBK195457/ PubMed PMID: 24741734. 13: Delev DP. Ulipristal acetate--a review of the new therapeutic indications and future prospects. Folia Med (Plovdiv). 2013 Jul-Dec;55(3-4):5-10. Review. PubMed PMID: 24712276. 14: Biglia N, Carinelli S, Maiorana A, D'Alonzo M, Lo Monte G, Marci R. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther. 2014 Feb 20;8:285-92. doi: 10.2147/DDDT.S54565. eCollection 2014. Review. PubMed PMID: 24591818; PubMed Central PMCID: PMC3934585. 15: Mozzanega B, Gizzo S, Di Gangi S, Cosmi E, Nardelli GB. Ulipristal acetate: critical review about endometrial and ovulatory effects in emergency contraception. Reprod Sci. 2014 Jun;21(6):678-85. doi: 10.1177/1933719113519178. Epub 2014 Jan 18. Review. PubMed PMID: 24440997. 16: Monleón Sancho J, Romaguera E, Romero A, Higueras G, Morcillo I, Fuster S. [Ulipristal acetate, 5mg: a new alternative]. Med Clin (Barc). 2013 Jul;141 Suppl 1:40-6. doi: 10.1016/S0025-7753(13)70052-6. Review. Spanish. PubMed PMID: 24314567. 17: Szamatowicz M, Kotarski J. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women]. Ginekol Pol. 2013 Mar;84(3):219-22. Review. Polish. PubMed PMID: 23700851. 18: Talaulikar VS, Manyonda IT. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids. Adv Ther. 2012 Aug;29(8):655-63. doi: 10.1007/s12325-012-0042-8. Epub 2012 Aug 16. Review. PubMed PMID: 22903240. 19: Wilton JM. Ulipristal acetate: the newest emergency contraceptive. Nurs Womens Health. 2012 Aug-Sep;16(4):331-5. doi: 10.1111/j.1751-486X.2012.01752.x. Review. PubMed PMID: 22900810. 20: Martinez AM, Thomas MA. Ulipristal acetate as an emergency contraceptive agent. Expert Opin Pharmacother. 2012 Sep;13(13):1937-42. doi: 10.1517/14656566.2012.705832. Epub 2012 Jul 7. Review. PubMed PMID: 22770536.